Assessment of the Effect of Spa Therapy on the Quality of Life of Patients With Chronic Venous Insufficiency (NEYRAC) (NEYRAC)

Evaluation of the Effectiveness of a Phlebology-oriented Spa Treatment on the Quality of Life of Patients Suffering From Chronic Venous Insufficiency of the Lower Limbs, 6-month After the Spa Treatment

Evaluation of the effectiveness of a phlebology-oriented spa therapy at 6 months on the quality of life of patients suffering from chronic venous insufficiency of the lower limbs

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

NEYRAC is a:

  • prospective, before/after, cohort follow-up study with repeated measurements
  • monocentric study with the dispensation of a 3-week phlebology-oriented spa therapy in Neyrac-les-Bains

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Age greater than 18 years
  • Patient with chronic venous insufficiency of the lower limbs (CEAP category C4a, C4b and C4c)
  • Patient presenting an indication for a phlebology-oriented spa treatment as the primary orientation. Patients with a dermatological or rheumatological pathology can benefit from a dual orientation spa treatment with a main phlebology orientation
  • Patient affiliated to the social security system or such a system
  • Available for an 18-day spa treatment and a 6-month follow-up
  • For women of childbearing age: effective contraception
  • Patient close to a study investigator (excluding teleconsultation) If not patient with access to the necessary equipment to perform a teleconsultation (smartphone, tablet or computer with an internet connection + taking and sending photos of the lower limbs)

Non inclusion criteria:

  • Venous surgery or venous interventional therapy within 3 months prior to inclusion or scheduled within the next 3 months
  • History of venous ulcer
  • Contraindication to spa therapy (immune deficiency, evolving cardiopathy neoplasia, infection, pulmonary tuberculosis, severe renal insufficiency, alcoholic cirrhosis, advanced senility and severe mental disorders)
  • Predictable intolerance to thermal treatments (intolerance to heat, baths, etc.)
  • Persons suffering from venous insufficiency of the varicose vein type (category CEAP C2) or edema alone (category CEAP C3) or open or healed ulcers (CEAP category C5 and C6)
  • Patient who has already undergone a phlebology-oriented spa treatment within the current thermal season
  • Subject already included in an interventional clinical research protocol
  • Persons referred to in articles L1121-5 to L1121-8 of the "Code de la Santé Publique" (pregnant women, women in labour and parturient and nursing mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure or not being able to verbally communicate their agreement, minor)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: patient treated with a phlebology-oriented spa therapy
Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
Other Names:
  • spa treatment
  • spa care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the effectiveness of a complete phlebology-oriented spa therapy on the quality of life of patients suffering from chronic venous insufficiency of the lower limbs
Time Frame: 6 months

Comparison of the mean scores of the Chronic Venous Insufficiency specific Quality of life questionnaire (CIVIQ20) at baseline and at 6 months.

The 20-item questionnaire, which provides a global index and an outline of 4 quality-of-life dimensions-"pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items).

Items on the CIVIQ-20 scale were scored from 1 to 5 which means a total score from 20 to 100.

A higher score means a worse outcome.

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of Visual Analog Scales (VAS) for pain at enrolment and 1.5, 3, 4.5 and 6 months after enrolment (post-cure) to quantitatively assess the improvement of patients' pain before/after treatment
Time Frame: 1.5, 3, 4.5 and 6 months

Comparison of the means of Visual Analog Scales (VAS) at enrolment an 1.5, 3, 4.5 and 6 months after enrolment.

Score from 0 to 100. A higher score means a worse outcome.

1.5, 3, 4.5 and 6 months
Assessment of the global quality of life by the EuroQol 5 Dimensions 5 Levels questionnaire (EQ5D-5L).
Time Frame: 3 and 6 months

Improvement in global quality of life (EQ5D-5L questionnaire) between enrolment and at 3 and 6 months after enrolment

The EQ5D-5L essentially consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).

There are five dimensions assessed in the descriptive system: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

Score from -0.53 to 1. A higher score means better outcome.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Score from 0 to 100. A higher score means better outcome.

3 and 6 months
Physician/Patient perception
Time Frame: 3 and 6 months

The perception of the physician and the patient will be asked to evaluate the benefit of the spa therapy, 3 and 6 months after enrolment using a 5-point Likert scale.

There are no numerical scores, only results in % of patients improved or worsened.

3 and 6 months
Medication consumption
Time Frame: 6 months

Collection of medication consumption to evaluate the benefit of the spa therapy (comparison of consumption before and after treatment)

To avoid any risk of confusion, medication consumption will be set to the daily consumption. Medication use for 72 hours (D-2, D-1, D0)

Medication consumption day before yesterday/yesterday/today:

  • Anticoagulant
  • Veinotonic

In the 3 months prior to the visit:

Medication use will be assessed by the investigating physician who will have to specify if this one is consumed because of the venous insufficiency or of another pathology

6 months
Assessment of compression compliance
Time Frame: 3 and 6 months
Comparison of the self-reported compression compliance (percentage of wearing time in the last week), between baseline and 3 and 6 months after enrolment
3 and 6 months
Evolution of the CEAP (Clinical Etiology Anatomical distribution Pathophysiology) category
Time Frame: 3 and 6 months

Comparison of CEAP category assessed by the investigating physician between enrolment and 3 and 6 months after enrolment

The basic principles of the CEAP classification include a description of the clinical class (C) based on objective signs, the etiology (E), the anatomical distribution (A) of reflux and obstructions in superficial, deep and perforating veins and the underlying pathophysiology (P), whether related to reflux or obstructions.

Only the clinical class (C) and the etiology (E) will be assessed.

3 and 6 months
Evolution of the general clinical criteria : Body Mass Index (BMI)
Time Frame: 3 and 6 months
Comparison of the Body Mass Index between enrolment, and 3 months and 6 months after enrolment
3 and 6 months
Evolution of the general clinical criteria : systolic blood pressure
Time Frame: 3 and 6 months
Comparison of the systolic blood pressure between enrolment, and 3 months and 6 months after enrolment
3 and 6 months
Evolution of the general clinical criteria : diastolic blood pressure
Time Frame: 3 and 6 months
Comparison of the diastolic blood pressure between enrolment, and 3 months and 6 months after enrolment
3 and 6 months
Evolution of the general clinical criteria : heart rate
Time Frame: 3 and 6 months
Comparison of the heart rate between enrolment, and 3 months and 6 months after enrolment
3 and 6 months
Evaluation of the Rutherford score at enrolment and at 3 months and at 6 months after enrolment to estimate the clinical severity of venous insufficiency
Time Frame: 3 and 6 months

Comparison of mean scores between enrolment and 3 months and 6 months after enrolment.

The Rutherford questionnaire is the Venous Clinical Severity Score (VCSS) questionnaire without the compression part.

The Rutherford questionnaire includes 9 hallmarks of venous disease, each scored on a severity scale from 0 to 3. In order to generate a dynamic score, the categories are scored individually, which adds emphasis to the most severe sequelae of venous disease that are likely to show the greatest response to therapy. These include skin changes and pigmentation, inflammation and induration, and ulcers (including number, size, and duration).

Score from 0 to 27. A higher score means a worse outcome.

3 and 6 months
Evaluation of the use of care related or not to venous insufficiency 6 months post enrolment
Time Frame: 6 months
Collection of medical events related or not to venous insufficiency (number of SAE, number of hospitalizations, number of medical and paramedical procedures)
6 months
Evaluation of compliance with the spa therapy
Time Frame: 3 weeks
Comparison of the thermal treatments received by the patient during the spa therapy with the thermal treatments prescribed by the thermal doctor at the start of the spa therapy, collected in the spa treatment booklet
3 weeks
Evaluation of the specific quality of life by the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire
Time Frame: 3 and 6 months

Quantitative improvement of the health status of all patients by comparison of the mean of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline, 3 months and 6 months for all patients, and then only for patients with osteoarthritis

The WOMAC is the validated index for the assessment of lower limb osteoarthritis according to a Likert scale with 5 possible answers (none = 0; minimal = 1; moderate = 2; severe = 3; extreme = 4) Scores from 0 to 100. A higher score means a worse outcome.

3 and 6 months
Comparison of the effictiveness of the treatment according to the limitation of the patient's walking (subgroup analysis according to patient mobility)
Time Frame: 6 months

Comparison of the primary endpoint Chronic Venous Insufficiency specific Quality of life questionnaire (CIVIQ20) according to the limitation of the patient's walking (limitation of the walking is self reported by the patient)

The 20-item questionnaire, which provides a global index and an outline of 4 quality-of-life dimensions-"pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items).

Items on the CIVIQ-20 scale were scored from 1 to 5 which means a total score from 20 to 100.

A higher score means a worse outcome.

6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 11, 2022

Primary Completion (Anticipated)

July 1, 2023

Study Completion (Anticipated)

July 1, 2023

Study Registration Dates

First Submitted

June 23, 2022

First Submitted That Met QC Criteria

July 4, 2022

First Posted (Actual)

July 8, 2022

Study Record Updates

Last Update Posted (Actual)

December 30, 2022

Last Update Submitted That Met QC Criteria

December 29, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2021-A00545-36

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Venous Insufficiency

Clinical Trials on Spa therapy

3
Subscribe